UOC
CNTX icon

UBS O'Connor’s Context Therapeutics CNTX Stock Holding History

UBS O'Connor’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-67,631
Closed -$41.4K – 398
2025
Q1 		$41.4K Sell
67,631
-241,127
-78% -$210K ﹤0.01% 289
2024
Q4 		$324K Hold
308,758
– – 0.01% 308
2024
Q3 		$605K Buy
308,758
+15,000
+5% +$33.3K 0.01% 332
2024
Q2 		$589K Sell
293,758
-2,917
-1% -$5.03K 0.02% 356
2024
Q1 		$409K Hold
296,675
– – 0.01% 347
2023
Q4 		$335K Buy
296,675
+975
+0.3% +$1.05K 0.01% 383
2023
Q3 		$447K Buy
295,700
+230,072
+351% +$260K 0.01% 411
2023
Q2 		$105K Buy
+65,628
New +$55.8K ﹤0.01% 490

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

UBS O'Connor's CNTX Position: Q2 2025 in Review

UBS O'Connor sold out of Context Therapeutics (CNTX) in Q2 2025, closing a stake of 67,631 shares — an estimated $41.4K sold.

UBS O'Connor first reported a position in CNTX in Q2 2023 and held it in 8 quarters. The position peaked at $605K in Q3 2024. 39 funds tracked by Wall St. Rank hold CNTX as of Q2 2025.

  • UBS O'Connor reported no remaining Context Therapeutics position as of Q2 2025 after selling out during the quarter.
  • UBS O'Connor sold 67,631 Context Therapeutics shares in Q2 2025, an estimated $41.4K.
  • UBS O'Connor first reported a position in Context Therapeutics in Q2 2023 and held it in 8 quarters.
  • UBS O'Connor's Context Therapeutics position peaked at $605K in Q3 2024.
  • 39 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2025.

Based on UBS O'Connor's 13F filing for Q2 2025, filed 14 Aug 2025.